Cancersareabletogrowbysubvertingimmunesuppressivepathways,topreventthe malignant cells as being recognized as dangerous or foreign. This mechanism prevents the cancer from being eliminated by the immune system and allows disease to progress from a very early stage to a lethal state. Immunotherapies are newly developing interventionsthatmodifythepatient'simmunesystemtofightcancer,byeitherdirectly stimulating rejection-type processes or blocking suppressive pathways.
| EXTRACELLULAR ATP RELEASE
andplateletactivation. 4 Importantly, eATP levels rise significantly in response to tissuedisturbingevents,includinginflammation,hypoxia,orischemiaaswell as in the setting of malignancy. 5, 6 Regulated ATP release may occur independently of membrane damage and may be mediated through ATP-bindingcassette(ABC)transporters,vesicularrelease,orchanneldependentmechanisms,theselatterincludingpannexins(Panx)orhemichannelconnexins(Conx). 6 OfthePanxisoformsthathavebeenidentifiedsofar,Panx1has
been the most studied, having an important role in the regulation of the blood flow, cell apoptosis, and inflammasome activation.
7,8
Among the Conx hemichannels, Conx37 and Conx44 mediate ATP release from monocytes, neutrophils, and endothelial cells during inflammatoryconditions.
9,10
ReleaseofATPandADPduringinflammatory processes occurs also from platelet dense granules through an exocytosis-mediatedmechanism.
11

| PURINERGIC TYPE 2 RECEPTOR SIGNALING BY ATP
Once in the extracellular milieu, ATP mediates inflammatory effects upon binding to cell surface type 2 (P2) purinergic receptors, 12 namely ligand-gated ion channel receptors (P2XRs) and G-protein-coupled receptors (P2YRs). There are seven P2XR and eight P2YR, which are virtually expressed on all mammalian cells.
13
Activation of these receptorscanmediateacuteprocessesthatmayinfluencemetabolism, adhesion, activation, or cell migration or more protracted reactions, likethoseobservedduringchronicinflammatoryresponses. activation of P2Y2R and P2X7R promotes DC activation and chemotaxis, 17 and activation of P2Y11R inhibits IL-12 and promotes IL-10 release by DCs 18 and has beenlinkedtoactivationofgranulocytes. 19 When considering adaptive immunity, T-cell activation has been found to result upon ATP binding to a number of P2XR, including P2X1R, P2X4R, P2X5R, and P2X7R. [20] [21] [22] [23] P2X7Rhasbeenspecificallyassociatedwithactivationof bothCD4andCD8effectors, 21, 24, 25 iNKTcells, 26 inductionofapoptosis by Tregs, 27, 28 andinhibitionofTr1celldifferentiation,asrecently reported. 29 While high ATP levels are associated with increased T-cell effectorfunction, 25 lowATPdosesplayatrophiceffectinthetumor microenvironment (TME) and may be associated with tumor growth promotion 30, 31 andmetastaticspread.
32
| SCAVENGING OF EATP OR OTHER NUCLEOTIDES AND GENERATION OF ADENOSINE AND/OR RESPECTIVE NUCLEOSIDES
ATPandothernucleotidesarerapidlyhydrolyzedtogenerateadenosine monophosphate (AMP) and ultimately adenosine, which has opposing effects to those mediated through the P2 receptor signaling. 33, 34 Different CD39 splicing products havebeenalsoidentified.
45
As do all NTPDases, CD39 has five highly conserved sequence domains, known as the "apyrase conserved regions," which are involved in active site formation and extracellular nucleotide catalysis byphosphohydrolysis.ENTPDalsosharescommonsequencemotifs aswellassecondaryandtertiarystructuresimilaritieswithmembers oftheactin/HSP70/sugarkinasesuperfamily. 46 CD39 is anchored to the cell membrane via two transmembrane domains that are essential for maintaining the catalytic activity and the specificity for the substrate. 47, 48 CD39 undergoes functional modifications, including limitedproteolysisandglycosylation,thelatterbeingdeterminantin conferring catalytic activity to CD39. 49 CD39 N-terminal intracytoplasmic domain undergoes palmitoylation to enable the enzyme associationwiththelipidrafts.
50-52
Experimentscarriedouttointerfere withcholesterollevelsviadrugs,whichareeitherdepletingorsequestering membrane cholesterol, have shown strong inhibition of the CD39ectoenzymaticactivity.
52
CD73 is a GPI-anchored enzyme that hydrolyzes AMP into adenosine and inorganic phosphate. 33, 53 CD73 also exists as a soluble form upon shedding of the GPI anchor, with similar activity to its membrane-bound form. 54, 55 From a structural point of view, CD73 is organized in three domains: (i) one N-terminal domain containing metal bindingsites;(ii)oneC-terminaldomaincontainingthecatalyticsite;
and(iii)oneshortalphahelixbridgingtheN-andC-terminaldomains.
CD73glycoformswithdifferentmolecularweightsandenzymaticac-tivitieshavebeendescribed.
56,57
FunctionalCD73consistsofanon-covalently linked homodimer stabilized by hydrophobic interactions between adjacent C-terminal domains. CD73 homodimerization, as wellasthebindingoftwozincions,arerequiredforcatalyticactivity.
CD73homodimersexistintwoconformations:openandclosed.
58,59
Hydrolysis of AMP requires that the enzyme cycles through open and closedconformationalstates.
| ECTONUCLEOTIDASES AND IMMUNOMODULATION
WehereafterreviewthefunctionalpropertiesofCD39andCD73on
immune and vascular cells, with a focus on lymphoid, myeloid, and endothelial cells.
In human peripheral blood, CD39 is constitutively expressed on >90% of B cells, >90% of monocytes, 20%-30% of CD4 + T cells (including memory T cells and Tregs), <5% of CD8 + T cells, and 2%-5%
of NK cells. Induction of CD39 is promoted upon exposure to proinflammatory cytokines (e.g., IL-6 and IL-27), oxidative stress and hypoxia, aryl hydrocarbon receptor (AhR) engagement by dietary compounds, and endogenous ligands (Longhi, unpublished).
Inhumanperipheralblood,CD73isexpressedonapproximately
75% of B cells, 50% of CD8 + T cells, 10% of CD4 + T cells, and 2%-5% ofNKcells.
60
Bcells,Tregs,Th17cells,NKcells,andmyeloid-derived suppressorcellscanco-expressCD39andCD73.Asearlyasin1977, reduced 5′-nucleotidase activity in blood lymphocyteswas noted in patientswithcommonvariableimmunodeficiency(CVI)andX-linked agammaglobulinemia (XLA).
Reduced CD73 expression in CVI and XLA patients is a consequence, rather than the cause, of defective lymphocyte development.
Consistent with this notion, decreased levelsofCD73expressiononlymphocyteshasbeendocumentedin patientswithHIV 61, 62 orinfectiousmononucleosis. 
63
| EFFECTOR T CELLS
| T REGULATORY TYPE 1 CELLS (TR1)
T regulatory type 1 (Tr1) cells represent a subset of regulatory lymphocytes characterized by secretion of IL-10, negativity for Foxp3 andexpressionofCD49bandLAG-3inbothmiceandhuman.
109,110
At variance with Foxp3 and TGF-β, though a cell contact-dependent mechanism has been also described and found to be associated with the expression of CTLA-4 and PD1.
111,112
Since their first description, Tr1 cells have been proven to be determinant in the maintenance of tolerance and immune homeostasis during hematopoietic stem cell transplanta-
Stat3. [113] [114] [115] [116] 
γδ T CELLS
CD73andCD39canbeexpressedonγδTcells,whichconstitutea prevalentT-cellpopulationinepithelialtissues.Incontrasttoclassical αβ T cells, γδTcellsrecognizediverseantigens,includingnon-classical MHC molecules, heat shock proteins, and lipids. 135 In tumors, γδ T cells can display cytotoxic or regulatory functions. Regulatory γδ T
cellscanexpresslatency-associatedpeptide(LAP),whichisconverted
to TGF-β1 by thrombospondin-1 (TSP-1). 136 Inmice,CD73isexpressedonmorethan90%ofperipheralγδ T cells.
137
CD73isexpressedinaTCR-ligandinduciblemannerandits expressionassociatedwithenrichmentoftranscriptionfactorslinked to effector function.
Yet, studies in CD73-deficient mice suggest that CD73 is dispensable for γδ T-cell development, 138 but may play aroleintheirregulatoryfunctions. 139, 140 In contrast, TCR-dependent
ATPreleaseandautocrinestimulationofP2X7Ronimmaturethymo-
cytes was shown to promote γδ T-cell development. In human, Vγ9Vδ2 T cells, whose function is to detect self and pathogen-associated phosphoantigens (pAgs), do not express CD73 norCD39,butcanupregulateCD39uponTCRstimulation. 145 It was proposedthatCD39upregulationuponγδTCRstimulationactsasa feedback mechanism to desensitize cells to self and microbial pAg.
Interestingly, CD39 was shown to dephosphorylate pAgs, rendering theminactiveatstimulatingγδ Τ cells. Therefore, interference with CD39 using CD39 inhibitors or blocking antibodiesmightrepresentastrategytokeepcell-mediatedimmunosuppressionundercontrolinthetumorsetting.
149
Expression of CD73 is virtually absent from circulating human andmouseNKcellsinhealthyindividuals.Tumor-infiltratingNKcells, however, can express significant levels of CD73. 
| B CELLS
CD39wasinitiallydescribedasaBlymphocyteactivationmarker.
42
Global deletion of CD39, as in CD39 −/− mice, does not alter the Bcell number in the peripheral blood and in the spleen. CD39 −/− mice, however,exhibitimpairedB-cellmemoryresponsestoT-dependent antigens,suggestingthatCD39maycontributetotheaffinitymatu-rationofantibodyresponseaswellaspostgerminalcenterB-celldifferentiation.
68
Human B cells have been found to co-express CD39
and CD73 and express A1, A2, and A3 adenosine receptors. 159 The A3 receptor was found to be specifically responsible for autocrine signaling and self-regulation. Generation of AMP and adenosine by CD73expressionhasbeenshowntopromoteBregfunction.CD73 expression indeed defines a population of murine B-1 and human IL-10-producing B cells with immunosuppressive activity toward T cells.
160,164
Notably,adenosine-producingBcellsproducesignificantly moreIL-10andIL-6,andactivationofA1andA2areceptorspromoted
expansionandfunctionsofadenosine-producingBcells.
| MYELOID CELLS
| Dendritic cells (DC)
DCs shape adaptive immunity through antigen presentation and modulation of T-cell activation. 
| ECTONUCLEOTIDASES AND VASCULAR REGULATION
ATP is known to modulate a variety of processes linked to endothe- 226 The involvement of endothelial cellspecificCD73andA2bhasbeendemonstratedinvitro.
210,227,228
Interestingly,thebarrier-protectingfunctionofCD73-derivedadenosine does not seem to be applicable to all types of endothelial surfaces.
Indeed, recent studies by the group of Bynoe indicate that the CD73-adenosine pathway rather favors the permeability and the entrance of immune cells at the blood-brain barrier (BBB) and blood-CSF barrier. 229 Using a murine model of EAE, this group demonstrated that CD73-derived adenosine and A2a receptor signaling is required for immune cell homingtothecentralnervoussystemandinductionofEAE.
230-232
Notably, a similar CD73/A2a-dependent pathway was shown to drive the recruitment of M2 macrophages in the CNS following spinal cord injury. 233 Inotherstudies,invivostimulationofA1andA2areceptorsusing specificagonistswasshowntotransientlyincreaseBBBpermeabilityto macromoleculesincludingantibodiesorchemotherapeuticagents, 234, 235 through both the paracellular and transcellular pathways.
234,236
Surprisingly, recent studies indicate that CD73 barrier-promoting function isnotactiveinthelymphatic endothelium, despitehighexpression of CD73.
227
TheroleoflymphaticCD73,thus,remainsunclear.
In the vascular endothelium, CD73 has been involved in lymphocyte adhesion and transmigration through endothelial barriers.
237,238
Lymphocytes adhering to CD73 + vascular endothelial cells can block CD73enzymaticactivity,therebyfavoringtheirtransmigrationacross the endothelium. 239 In human lymphatic endothelium, CD73 is expressed on afferent but not efferent lymphatic. 240 In murine lymph nodes,CD73isnotexpressedinlymphaticsinusesbuthighlyexpressed
on high endothelial venules (HEV).
241
UsingCD73-deficientmicesubcutaneouslyinjectedwithWT-orCD73-deficientlymphocytes,itwas demonstratedthatlymphatic CD73isnotinvolvedinleukocytetraf-fickingtolymphnodesinrestingorinflammatoryconditions.
240
Incontrast,lymphocytemigrationfromthebloodstreamtolymph
HEV-derived CD73 is modulating lymphocyte trafficking to lymph nodes.
241
This effect was reversed using a specificA2b agonist and
A2bwasshowntobethepredominantadenosinereceptorexpressed
by HEV. 241 Thus,localadenosineproductionbyCD73 + HEV followed byautocrinestimulationofA2bseemstobeamechanismrestricting lymphocyteextravasationfromthebloodstreamintolymphnodes.
Inhumans,CD73loss-of-functionmutationshavebeendescribed and linked to a rare autosomal-recessive disorder causing ectopic calcificationofjointandarteries(CALJA).Initiallyidentifiedinnineindividualsfromthreeunrelatedfamiliesin2011,arterialcalcificationdue toCD73deficiency(ACDC)hasbeenshowtospecificallytargetlower extremityarteries,aswellasofthehandandfootjointcapsules.
101,242
Recently, a second report from an independent Chinese group expandedtheclinicalportraitofACDCidentifyingnovelNT5Eloss-offunctionmutationsandshowingthatcalcificationcouldalsooccurred in upper extremity arteries. In accordance with these observations, a recent report by Li et al. 244 describedthedevelopmentjointcalcificationin11-to13-month-oldCD73-deficientmicefedwithadietrich inphosphateandlowinmagnesium.UnlikeACDCpatients,however, noarterialectopiccalcificationwasobservedinCD73-deficientmice.
| PURINERGIC SIGNALING AND CANCER
Thepurinergicsignalingsystemhasconsiderableeffectsontumorgrowth, survival,andprogression,byimpactingnotonlythetumoritselfbutalso the immune responses and the microenvironment associated with it.
In solid tumors, ATP is abundantly released in the extracellular spacewhere its concentration can reach a few hundred micromoles perliter,aconcentrationmorethanathousandtimeshigherthanin healthytissues. 5, 245 This phenomenon is mainly due to cell death in the tumorcore,andtometabolicorhypoxicstressandpro-inflammatory signalsthatstimulateactiveexportofATPbyconnexinsandpannexin channelsexpressedbyimmuneandendothelialcells. 6, 246 In the TME, eATP acts as a danger signal involved in the recruitment of innate immunecellsandintheprimingofanti-tumorimmunitythroughtheactivationofP2XandP2Yreceptors. 179, 180, 247 In support for a pivotal role ofP2purinergicreceptorsintheinitiationofanti-tumorimmunity,ATP release in the TME is considered as one of the three hallmarks (with calreticulinexposureandHMGB1secretion)oftheimmunogeniccell death (ICD) process. 6 However,intheTME,extracellularATPismost 
P2XRandP2YRarewidelydistributedintumortissues,anditis
well established that virtually all cancer cell lines respond to extracellularnucleotides,includingATP.
5,254
MosttumorsexpressP2X7R, theactivationofwhichhasbeenclassicallylinkedtocytotoxiceffects, althoughgrowingevidencehasalsoassociatedthestimulationofthis ATP receptor with tumor growth.
5,246
WhilehighATPconcentrations trigger cytotoxic P2X7R responses, low-doseATP results in P2X7R-mediated trophic effects. 31, [255] [256] [257] [258] There is also evidence that both cancer cells and other cells present in the TME may be resistant to high tumor growth. 274 In other in vitro studies where we studied Luc-B16/ F10 melanoma cells, we observed that ATP-induced alterations in tumorcellgrowthwerenullifiedfollowingtreatmentwithapyrase,a solubleformofCD39andthatthiseffectwasdosedependent. 224 In additionalexperimentsinwhichLuc-B16/F10cellswereco-cultured withliversinusoidalendothelialcells(LSEC)andexposedtoATP,we demonstratedthatexpressionofCD39byLSECcounterbalancesthe inhibitoryeffectexhibitedbyATPontumorgrowth.
| CD39 IN TUMOR IMMUNITY
224
Treatment with POM1, a pharmacological CD39 inhibitor, was also shown to significantly limit the tumor growth.
274
Deletion of CD39 or direct inhibition also potently suppresses tumor angiogenesis in several models tested to date.
92,224,275
GeneticdeletionofCD39with abrogationofangiogenesisresultsindecreasedgrowthofimplanted LLCandB16-F10tumorswhileinhibitingdevelopmentofpulmonary metastases. 275 Decreases in Cd39-null endothelial cell adhesion and integrindysfunctioncanbelinkedtodecreasedactivationofFAKand extracellularsignaling-regulatedkinase-1andkinase-2inthesecellu-lar models.
275,276
Collectively, all these studies support an inverse correlation be- CD73-deficient mice are also resistant to lung metastasis development following tail-vein injectionsofB16F10melanomaandTRAMP-C1prostatecancercells.
| CD73 IN TUMOR IMMUNITY
95,277
Depending on the models, the tumor-protective effect of CD73 
| CD39 IN HUMAN CANCERS
ExpressionofCD39byhumantumorsandinfiltratingimmunecellshas been widely described, and, in some studies, it has been proposed as a prognosticmarker.CD39hasbeenfoundtobeelevatedinpancreatic cancerandispreferentiallyexpressedbythevasculatureandstromal elements.
280
High-tissue CD39 mRNA levels correlated with better long-termsurvivalaftertumorresection. 
94
ExpressionofCD39isassociatedwithgenerationofadenosinethat hasinhibitoryroleoneffectoranti-tumorimmunity.
In patients with chronic lymphocytic leukemia (CLL), high CD39 expression was observed in both CD4 and CD8 cells and found to be associated with an advanced disease stage. 283 In another study by Perry et al. OtherstudieshaveidentifiedCD73asamarkerofgoodprogno-sis, including in low-grade breast cancers 294 and endometrial carcinomas. 295 Inendometrialcancer,lossofCD73expressioninendometrial
| CD73 IN HUMAN CANCERS
tumors was shown to disrupt the endometrial epithelial barrier integrity thereby favoring tumor progression.
295
This observation is in accordancewiththewell-describedbarrier-protectingroleofCD73-derivedadenosineinvascularendotheliumorintestinalepithelium.In endometrialepithelium,barrier-promotingfunctionofCD73-derived adenosine appears to be dependent on A1 receptor. 295 Whether CD73 acts as a tumor suppressor in the development of other types of cancersisanimportantquestionthatremainstobeaddressed.
Interestingly, recent data suggest that plasma concentrations of soluble CD73 (sCD73) are higher in cancer patients compared with healthy individuals. 296 Increased sCD73 levels in blood were also reported in patients with acute inflammatory pancreatitis. 
| TARGETING ECTONUCLEOTIDASES-EXPERIMENTAL AND CLINICAL STUDIES
Given ActivationofA2breceptorsontumorcellsislikelyan important mechanism by which CD73-adenosine promotes metastasis. 154, 271 Recently, A2b receptor signaling in tumor cells was shown to promoteERKactivationandFXYD5expression,aregulatorofcell-cell adhesion. 313 Other studies have linked A2b signaling to decreased cell adhesion through modulation of Rap1 localization.
314
Expression of
A2b receptor on tumor cells is at least partly regulated by the transcriptionfactorFOS-relatedantigen1(FRA-1).
315
Targeted blockade of CD73 also suppresses tumor angiogenesis.
Anti-CD73mAbtherapywasindeedshowntoreducevascularendo-thelial cells present in 4T1.2 tumors.
316,317
BothenzymaticandnonenzymaticfunctionsofCD73appeartopromotetumorangiogenesis.
Adenosine-dependentCD73activitystimulatedVEGFproductionand
FAKsignaling,whileadenosine-independentCD73activitypromoted theformationofcapillary-likestructuresbyendothelialcells. 316 Others havealsosuggestedaroleforCD73inpromotingtumorcelladhesion to extracellular matrix proteins. For instance, CD73 was shown to promote melanoma cell adhesion to Tenascin-C independently of its enzymaticactivity.
318,319
Afirst-in-classtherapeuticanti-CD73mAb,MEDI9447,iscurrently
which results in non-competitive inhibition its enzymatic activity.
320
MEDI9447 was shown to inhibit both membrane-bound and sCD73.
Data from MedImmune suggest that MEDI9447 induces bridging or cross-linking of CD73 dimers, restricting its necessary conformational change. 320 Intriguingly, MEDI9447 also blocks surface-bound 
307,321
Innate Pharma also reported a research program around anti-CD73
antibodies. Data presented showed that anti-CD73 mAbs inhibited enzymaticactivitycouldeffectivelyreverseAMP-mediatedT-cellsuppression in vitro. 322 Corvus Pharmaceuticals and Arcus Biosciences have also recently disclosed CD73 inhibitor programs. suggestingthattheCD73-A2baxiscouldbeatargetforTNBC.
| TARGETING ADENOSINE RECEPTORS
328
| COMBINATIONAL THERAPIES
Targeting multiple immunosuppressive pathways can synergistically enhanceanti-tumorimmuneresponses.
Asimmunecellsinfiltratingthetumorco-expressCD39inassocia-tionwithotherco-inhibitorymolecules(e.g.,CTLA4andPDL1),acombinational approach targeting both CD39, CD73, and co-inhibitory molecules has been proposed with the aim to control the immunosuppressivepotentialofadenosinesignalingwhileminimizingtheside effectsofanti-CTLA4andanti-PD1blockade. 
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